Preoperative vs Postoperative IMRT for Extremity/Truncal STS

Recruitment Status
ACTIVE, NOT RECRUITING
(See Contacts and Locations)Verified January 2024 by Mount Sinai Hospital, Canada
Sponsor
Mount Sinai Hospital, Canada
Information Provided by (Responsible Party)
Mount Sinai Hospital, Canada
Clinicaltrials.gov Identifier
NCT02565498
Other Study ID Numbers:
OCREB # 15-070
First Submitted
September 17, 2015
First Posted
September 30, 2015
Last Update Posted
February 19, 2024
Last Verified
January 2024

ClinicalTrials.gov processed this data on February 2024Link to the current ClinicalTrials.gov record .

History of Changes

Study Details

Study Description

Perioperative RT in addition to surgery is widely accepted as standard management for soft tissue sarcoma (STS) of the extremity and trunk. However, controversy remains as to whether RT should be delivered preoperatively or postoperatively. While both confer similar rates of local control, preoperative RT leads to a decrease in late tissue morbidities such as fibrosis, limb edema, joint stiffness and fracture as compared to postoperative RT. The reasons for this are likely multifactorial, but are in part related to total dose delivered (50 Gray (GY) preoperatively and 60-66 Gy postoperatively) and, based on a previous National Cancer Institute (Canada) Phase III randomized controlled trial, the much larger volume treated in the postoperative setting compared to that in the preoperative setting. The optimal radiation dose used in the postoperative setting is unknown but has been developed empirically and doses of 60-66 Gy are generally employed.However, investigators in Norway/Sweden and France have found equivalent local control rates for patients with negative surgical margins treated with 50 GY postoperativelyThe main concern with preoperative RT has centered on the risk of an increased rate of delayed wound healing and major wound complications. Although some studies suggest it may be possible to reduce the incidence of acute wound healing complications associated with pre-operative radiation than previously seen in the 2D RT era, this has yet to be tested in the phase III setting. IG-IMRT allows a much higher degree of conformality and accurate delivery of dose to the tumour while sparing surrounding normal tissue. This may allow similar rates of acute wound healing complications for pre- and postoperative RT in the treatment of STS.

Condition or DiseaseIntervention/Treatment
Adult Soft Tissue Sarcoma
Radiation: Preoperative intensity modulated radiation therapyRadiation: Postoperative intensity modulated radiation therapy

Study Design

Study TypeInterventional
Actual Enrollment210 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingNone (Open Label)
Primary PurposeTreatment
Official TitlePhase III Study of Preoperative vs Postoperative Intensity Modulated Radiation Therapy For Truncal/Extremity Soft Tissue Sarcoma
Study Start DateMay 31, 2016
Actual Primary Completion DateSeptember 30, 2024
Actual Study Completion Date2yrs 11mos from now

Groups and Cohorts

Group/CohortIntervention/Treatment
Preoperative Radiation Therapy (Arm A)
Preoperative intensity modulated radiation therapy followed by surgery
Radiation: Preoperative intensity modulated radiation therapy
50 Gy delivered in 25 fractions 4-6 weeks prior to surgical excision
Postoperative Radiation Therapy (Arm B)
Surgery followed by postoperative intensity modulated radiation therapy
Radiation: Postoperative intensity modulated radiation therapy
Surgery followed by 50 Gy delivered in 25 fractions within 6 weeks of surgery for patients with negative margins; for patients with positive margins a boost of 16 Gy in 8 fractions will be added.

Outcome Measures

Primary Outcome Measures
  1. Incidence of acute wound healing complications
    * Secondary operations required for wound treatment (debridement, secondary closure procedures such as rotationplasty, free flaps or skin grafts); * Readmission to hospital for wound care; * Invasive procedures required for wound care (drainage of hematoma, seroma or infected wound collection); * Deep wound packing required at any time (deep packing defined as packing deep to dermis in an area of dehisced wound) to an area of the wound measuring at least 2 cm in length; * Prolonged dressing changes, including packing of the wound for greater than six weeks from wound breakdown; * Repeat surgery for revision of a split thickness skin graft or requirement for wet dressings for longer than four weeks. (It is permissible for a patient to protect a totally epithelialized skin graft with a dry dressing without declaring a major wound complication) * Use of vacuum-assisted closure (VAC)
Secondary Outcome Measures
  1. Acute Radiation Toxicity
    Acute radiation skin toxicity will be documented according to the Radiotherapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring Criteria.
  2. Late Radiation Toxicity- RTOG Late Radiation Morbidity
    Late radiation morbidity to skin, subcutaneous tissue, bone and joints will be documented according to the RTOG/EORTC Late Radiation Morbidity Scoring Scheme.
  3. Late Radiation Toxicity- Common Toxicity Criteria
    Late radiation morbidity to skin, subcutaneous tissue, bone and joints will be documented according to the Common Toxicity Criteria v4.0
  4. Late Radiation Toxicity- Limb Edema
    Peripheral limb edema will be documented according to the Late Limb Edema Scoring Criteria.
  5. Limb Function
    Limb function will be documented according to the Musculoskeletal Tumor Society Rating Scale.
  6. Patient function
    Patient function will be documented according to the patient completed Toronto Extremity Salvage Score (TESS)
  7. Overall Survival
    Overall patient survival in months during the study period
  8. Local recurrence-free survival
    Patient survival without a local recurrence in months during the study period.
  9. Metastasis-free survival
    Patient survival without systemic metastases in months during the study period.

Eligibility Criteria

Ages Eligible for Study(Adult, Older Adult)
Sexes Eligible for StudyAll
Accepts Healthy VolunteersNo
Inclusion Criteria
1. Histologically proven soft tissue sarcoma of the extremity or trunk following review by local reference pathologist. 2. Deemed appropriate for preoperative or postoperative radiotherapy and conservative surgery following patient assessment by a radiation oncologist and surgical oncologist. 3. Lesion is primary or locally recurrent. Patient may have undergone excisional biopsy with positive margins at a referring hospital and are eligible following discussion among the surgical oncologists and radiation oncologists that IMRT is an acceptable treatment for that case. 4. Eastern Cooperative Oncology Group (ECOG) score 0-3 5. Patient is aged 18years or older. 6. Patient is able to provide informed consent 7. Patient is available for treatment and follow-up.
Exclusion Criteria
1. Benign histology. 2. Prior malignancy within the previous five years or concurrent malignancy with the exception of adequately treated basal cell carcinoma of the skin or carcinoma in-situ of the cervix. 3. Prior radiotherapy to the target site 4. Planned chemotherapy for (neo)adjuvant treatment 5. Conservative surgery to the target site 6. Presence of regional nodal disease or unequivocal distant metastases. 7. Other major medical illness deemed to preclude safe administration of protocol treatment or required follow-up.

Contacts and Locations

Sponsors and CollaboratorsMount Sinai Hospital, Canada
Locations
Dana Farber Cancer Institute | Boston Massachusetts, United States, 02215Cleveland Clinic Taussig Cancer Institute | Cleveland Ohio, United States, 44195Oregon Health & Science University | Portland Oregon, United States, 97239-3098Cliniques Universitaires Saint-Luc | Brussels , Belgium, The Ottawa Hospital Cancer Centre | Ottawa Ontario, Canada, K1H 8L6Mount Sinai Hospital | Toronto Ontario, Canada, M5G 1X5Princess Margaret Cancer Centre | Toronto Ontario, Canada, M5G 2M9Hopital Maisonneuve-Rosemont | Montreal Quebec, Canada, H1T 2M4
Investigators
Principal Investigator: Peter Ferguson, MD, FRCSC, MOUNT SINAI HOSPITALPrincipal Investigator: Peter Chung, MD, Princess Margaret Cancer Centre